Tan, Nicholas E. http://orcid.org/0000-0002-7362-0038
Chen, Shannon X. http://orcid.org/0000-0002-5050-6064
Radcliffe, Nathan M. http://orcid.org/0000-0003-3976-6831
Funding for this research was provided by:
Alpha Omega Alpha Honor Medical Society
Article History
Received: 16 March 2022
Revised: 12 July 2022
Accepted: 19 July 2022
First Online: 26 August 2022
Declarations
:
: This research study was conducted retrospectively from data obtained for clinical purposes. An IRB official waiver of ethical approval was granted from the Sterling IRB. All research was performed in accordance with the Health Insurance Portability and Accountability Act of 1996 and adhered to tenets of the Declaration of Helsinki.
: The need for informed consent was waived owing to the retrospective study design.
: This study was supported in part by an Alpha Omega Alpha Carolyn L Kuckein Student Research Fellowship. Author NMR reports the following: CATS LLC—Consultant (C). Allergan—C, Speaker (S). Alcon—C, S. Novartis—C, S. Ellex—C. Eyenovia—C. Lumenis—C. ELT Sight—C, Equity (E). Equinox—C, Investor (I). Iridex—C. Aerie—C, S. Bausch & Lomb/Valeant—C, S. BVI—C, S. Eyepoint—C. Ivantis—C, S. Glaukos—C, S. Alimera—C, S. Kala Lumenis Inc—C, S, New World Medical—C, S. SpyGlass—C. Sight Sciences—C, S. Santen, Inc—C. Thea—C. Reichert—C. Shire—C. Carl Zeiss Meditec—C. Ocular Science—C. Ocular Therapeutix—C. Omeros—C. Quantel Medical—C. ViaLase—C. The authors have no other competing interests to declare that are relevant to the content of this article.